as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will make ONAPGO available in ...

Opens in a new tab or window The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus ...

The funding comes from UK-based investor JuvVentures. The company says it is leveraging its own drug-delivery technology to make an existing Parkinson’s medication, apomorphine, more effective ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the ...

Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s disease. Onapgo reduced “off” time, as well as increased “good on” time ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous infusion ...

(SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in adults with advanced Parkinson's ...